WS Audiology delivered 4% organic revenue growth in the first quarter of FY 2024/25
Lynge, Denmark – February 6, 2025 – WS Audiology (WSA), a leading pure play hearing healthcare group, today announced results for the first quarter of the financial year 2024/25 in line with expectations (October 1, 2024 – December 31, 2024). Jan Makela, CEO of WSA, said: With an organic revenue growth of 4%, we are off to a good start of the financial year on a high comparative base from last year. Growth continues to be driven by solid performances across all regions and channels, based on our two strong and complementary brand platforms Signia and Widex. We look forward to launching new advanced hearing solutions on both platforms in the coming months, reaffirming our commitment to improving hearing care for all and simplifying the customer journey. Q1 FY 2024/2025 highlights (Q1 last financial year in brackets) WSA delivered organic revenue growth of 4% (13%) to EUR 670 million in line with expectations and driven by continued solid performance across regions and channels based on our two strong and complementary brand platforms Signia and Widex. Revenue growth in Q1 last year (13%) was positively impacted by the launch in key markets of our Signia IX platform, which significantly improves users’ ability to participate in noisy group conversations by delivering more than twice the speech enhancement benefit compared to other leading hearing aids[1]. Signia IX continues to be a key growth driver across all regions. Revenue growth was broad based with 4% organic growth in all three regions (Americas, EMEA, APAC). Online continued the high growth of previous quarters. EBITDA[2] was EUR 114 million corresponding to an EBITDA margin of 17.0% (16.4%) in line with expectations. Marianne Vinding Ovesen has joined as Chief Operating Officer, bringing valuable experience from diagnostics and life science from Danaher Corporation, Radiometer and Coloplast to WSA. Carsten Buhl, Regional President for WSA Americas, has joined the Executive Board alongside CEO Jan Makela and CFO Marianne Wiinholt, reflecting the importance of the Americas organization in driving profitable growth for WSA in the future. Financial year 2024/25 outlook Outlook for the financial year 2024/25 is maintained at 3-6% organic revenue growth supported by our competitive product portfolio and upcoming launches. The EBITDA margin before special items is expected to increase by 1-2%-points supported by our profitable growth program to drive future margin improvements. [1] Jensen NS, Wilson C, Kamkar Parsi H, Samra B, Hain J, Best S & Taylor B. 2024. Signia IX delivers more than twice the speech enhancement benefit in a noisy group conversation than the closest competitors. Signia White Paper. [2] Measured as EBITDA before special items and net of R&D Capex. About WS Audiology WS Audiology (WSA) is a leading global pure-play hearing healthcare group, pioneering innovative technologies for over 140 years, helping millions of people with hearing loss regain their hearing, engage in meaningful conversations, and participate fully in society. WSA operates in over 130 markets and employs more than 12,500 people across our innovative brand platforms, Widex and Signia, and a global network of hearing care professionals and consumer-facing businesses. WSA is privately owned by the Tøpholm and Westermann families, the Lundbeck Foundation, and EQT-managed funds. Learn more at www.wsa.com.
Subscribe to releases from WS Audiology
Subscribe to all the latest releases from WS Audiology by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from WS Audiology
Carsten Buhl to leave WSA10.6.2025 00:00:00 CEST | Press release
Lynge, Denmark, June 10, 2025 – WSA, a leading pure-play hearing healthcare group, today announced that Carsten Buhl, member of the Executive Committee and Executive Board of WSA, and President of its Americas Region, has decided to pursue a new career outside WSA and to leave the company on August 31, 2025. Carsten Buhl joined WSA in 2019, where he first served as President of the EMEA-LATAM-Canada region, next to being a member of WSA’s Group Management Team. In 2022 he was appointed President of the Americas Region. WSA CEO Jan Makela commented: We are sorry to see Carsten go and will certainly miss his constructive leadership style, as well as his deep insights into the hearing care market. We are happy for him as we part ways on positive terms. We are grateful for his many contributions to our company, and we wish him every success! Carsten Buhl said: “I am proud of my journey at WSA and what we have achieved together working with a fantastic group of highly motivated colleagues.
Dorothea Wenzel joins WSA’s Board of Directors and is appointed Chair of the Audit Committee2.6.2025 00:00:00 CEST | Press release
Lynge, Denmark, June 2, 2025 – WSA, a leading pure-play hearing healthcare group, is pleased to announce that Dorothea Wenzel has joined its Board of Directors and has been appointed Chair of the Audit Committee, effective immediately. At the same time, Julian Tøpholm is stepping down from the Board. Ms. Wenzel joins as an independent director with an impressive track record in finance and strategy leadership across multiple industries, including a long career at the biopharmaceutical company Merck, where she held several commercial and financial executive positions. She has extensive experience in leading business transformations, and significant board experience from Dentsply Sirona Inc., Servier Group, Gerresheimer, and as Lead Independent Director at Fresenius Medical Care AG & Co. Most recently, she was appointed Chair of Lundbeck, following her tenure as Chair of its Audit Committee. WSA Chair Lars Rasmussen commented: We are delighted to welcome Dorothea to the WSA Board. Her br
WSA delivered 1% organic revenue growth and increased EBITDA by 22% in the second quarter of FY 2024/258.5.2025 00:00:00 CEST | Press release
Lynge, Denmark – May 8, 2025 – WSA, a leading pure-play hearing healthcare group, today announced results for the second quarter of the financial year 2024/25 (January 1, 2025 – March 31, 2025) showing organic revenue growth of 1% and an increase in EBITDA of 22%, corresponding to an EBITDA margin improvement of 2.8%-points. Jan Mäkelä, CEO of WSA, said: With an organic revenue growth of 1% in a volatile macro environment and a significant EBITDA margin improvement, WSA delivered satisfactory second quarter results. I am very pleased with the successful launch of Signia BCT IX and Widex Allure at the end of the quarter. With our complementary and distinct Signia and Widex brand platforms, we are committed to delivering an uncompromising hearing experience that meets the unique needs of the largest groups of people with hearing loss and the hearing care professionals serving them.” Highlights Q2 2024/2025 (Q2 last financial year in brackets) WSA delivered organic revenue growth of 1% (7
WS Audiology Expands Indian Operations with New Commercial and Production Hub in Bangalore16.4.2025 00:00:00 CEST | Press release
Bangalore, India – 16 April 2025 – WS Audiology (WSA), a leading pure play hearing health care group, today announced the opening of its new office in Bangalore, further strengthening its footprint in India. The facility, operating as WS Audiology India, will serve as a key hub for commercial and production activities, supporting WSA’s long-term commitment to improve hearing health access across the country. The new Bangalore office reflects WSA’s belief in India’s growing role in the global hearing care landscape. According to the World Health Organization, an estimated 6.3% of India’s population suffers from significant hearing loss. WSA continues to lead the industry in making hearing care more accessible, affordable, and effective through its “Triple A” approach—Awareness, Affordability, and Accessibility. Supporting Growth, Enhancing Service “India has been one of our fastest-growing markets in APAC, and we’re incredibly proud of the work our teams have done here,” said Avinash Pa
WSA welcomes ATHOS KG as a new shareholder and receives new investment to support its long-term development11.4.2025 00:00:00 CEST | Press release
Lynge, Denmark – 11 April 2025 – WS Audiology (WSA), a leading pure play hearing health care group, today announced ATHOS KG as a new minority shareholder, as well as an equity capital injection of EUR c. 590 million in total from its existing and new shareholders to further support the company’s successful growth trajectory and long-term strategic ambitions. WSA welcomes ATHOS, a German healthcare focused single family office, as a new shareholder alongside T&W Medical, EQT, and the Lundbeck Foundation, which together continue to exercise joint control of WSA in an unchanged governance set-up. Lars Rasmussen, Chair of WSA, said: I am pleased by the strong commitment of WSA’s shareholders to the company’s continued growth and long-term development. The owners have decided to strengthen WSA’s financial foundation by injecting equity, which will further bring down WSA’s net leverage. At the same time, I am pleased to welcome ATHOS as a shareholder of WSA. With T&W Medical, EQT, the Lundb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom